Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Transplantation

• Publication date

  1989-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00007890-198902000-00035PMID 2465593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Establishment of an interleukin 6 (IL 6)/B cell stimulatory factor 2‐dependent cell line and preparation of anti‐IL 6 monoclonal antibodies

  1988cited by this paper
• B-cell-stimulatory factor 2 (beta 2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells.

  1987cited by this paper
• Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor

  1987cited by this paper
• STUDIES OF THE INDUCTION AND MAINTENANCE OF LONG‐TERM GRAFT ACCEPTANCE BY TREATMENT WITH FK506 IN HETEROTOPIC CARDIAC ALLOTRANSPLANTATION IN RATS

  1987cited by this paper
• Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.

  1987cited by this paper
• Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

  1986cited by this paper
• Structure and expression of cDNA and genes for human interferon‐beta‐2, a distinct species inducible by growth‐stimulatory cytokines.

  1986cited by this paper
• Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts.

  1986cited by this paper
• The effects of cyclosporin A on the immune system.

  1985cited by this paper
• Induction of a 26-kDa-protein mRNA in human cells treated with an interleukin-1-related, leukocyte-derived factor.

  1985cited by this paper
• Factors affecting B-cell growth and differentiation.

  1985cited by this paper
• Effect of B cell differentiation factor (BCDF) on biosynthesis and secretion of immunoglobulin molecules in human B cell lines.

  1985cited by this paper
• Interferons as macrophage-activating factors. III. Preferential effects of interferon-gamma on the interleukin 1 secretory potential of fresh or aged human monocytes.

  1985cited by this paper
• Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2).

  1985cited by this paper
• Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets.

  1983cited by this paper
• Secretory proteins induced in human fibroblasts under conditions used for the production of interferon beta.

  1982cited by this paper
• Cyclosporin A – Usefulness, Risks and Mechanism of Action

  1982cited by this paper
• A human helper T cell clone secreting both killer helper factor(s) and T cell-replacing factor(s).

  1982cited by this paper
• New simple dye-uptake assay for interferon.

  1981cited by this paper
• The role of interleukin-2 (IL-2) in the differentiatin of cytotoxic T cells: the effect of monoclonal anti-IL-2 antibody and absorption with IL-2 dependent T cell lines.

  1981cited by this paper
• T cell growth factor: parameters of production and a quantitative microassay for activity.

  1978cited by this paper
• T-T-cell interactions during the vitro cytotoxic allograft responses. I. Soluble products from activated Lyl+ T cells trigger autonomously antigen-primed Ly23+ T cells to cell proliferation and cytolytic activity

  1978cited by this paper

• Preparation and evaluation of novel oral tacrolimus nanocochleates for organ transplantation to reduce individual differences and improve drug safety.

  2024cites this paper
• Islet Cell Transplant

  2019cites this paper
• Tetramethylpyrazine (TMP) ameliorates corneal neovascularization via regulating cell infiltration into cornea after alkali burn.

  2019cites this paper
• Tacrolimus prevents murine cerebral malaria

  2017cites this paper
• Clinical Islet Cell Transplantation – Recent Advances

  2017cites this paper
• Autologous and Allogenous Antibodies in Lung and Islet Cell Transplantation

  2016cites this paper
• The effects of 8-arm-PEG-catechol/heparin shielding system and immunosuppressive drug, FK506 on the survival of intraportally allotransplanted islets.

  2013cites this paper
• Protocol TOP-Study (tacrolimus organ perfusion): a prospective randomized multicenter trial to reduce ischemia reperfusion injury in transplantation of marginal liver grafts with an ex vivo tacrolimus perfusion

  2013cites this paper
• Involvement of intestinal intraepithelial lymphocytes in turnover of intestinal epithelial cells: morphological and functional alterations due to daily administration of FK506.

  2012cites this paper
• Development of a robust method for establishing B cell lines using Epstein-Barr Virus

  2012cites this paper
• Surface camouflage of pancreatic islets using 6-arm-PEG-catechol in combined therapy with tacrolimus and anti-CD154 monoclonal antibody for xenotransplantation.

  2011cites this paper
• Evaluation of Amphotericin B and Micafungin Combination Against Clinical Isolates of Aspergillus Species

  2011cites this paper
• Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis

  2010cites this paper
• Synergistic effects of Isatis tinctoria L. and tacrolimus in the prevention of acute heart rejection in mice.

  2009cites this paper
• The effect of two novel C-type lectins, Ba100 and Ba25, isolated from the venom of the puff adder, Bitis arietans on T lymphocyte proliferative responses

  2008cites this paper
• Efficacy of transient treatment with FK506 in the early phase on cyclophosphamide-induced bone marrow chimerism and transplant tolerance across MHC barriers.

  2006cites this paper
• Acute Graft-Versus-Host Disease

  2006cites this paper
• Anti-inflammatory effect of spironolactone on human peripheral blood mononuclear cells.

  2006cites this paper
• FK506 ameliorates spontaneous locomotor activity in collagen-induced arthritis: implication of distinct effect from suppression of inflammation.

  2005cites this paper
• Conversion from cyclosporine A to tacrolimus in pediatric kidney transplant recipients with chronic rejection: Changes in the immune responses

  2004cites this paper
• FK506（タクロリムス）連続投与によるマウス小腸上皮細胞の形態的及び機能的変化

  2004cites this paper
• Investigation on the effects of topical therapy with 0.1% tacrolimus ointment (Protopic) on intradermal skin test reactivity in atopic dogs.

  2004cites this paper
• FK506 ameliorates proteinuria and glomerular lesions induced by anti-Thy 1.1 monoclonal antibody 1-22-3.

  2002cites this paper
• FK 506-mediated T-cell apoptosis induction.

  2001cites this paper
• Tacrolimus inhibits cytokine production and chemical mediator release following antigen stimulation of passively sensitized human lung tissues.

  2001cites this paper
• Coronary vasomotor dysfunction in the cardiac allograft: impact of different immunosuppressive regimens.

  2000cites this paper
• Systemic therapy of atopic dermatitis

  2000cites this paper
• FK506 attenuates developing and established joint inflammation and suppresses interleukin 6 and nitric oxide expression in bacterial cell wall induced polyarthritis.

  2000cites this paper
• The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.

  2000cites this paper
• Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation

  2000cites this paper
• Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate.

  1999cites this paper
• FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL.

  1999cites this paper
• A comparative investigation of FK506 and cyclosporin A in murine corneal transplantation

  1998cites this paper
• Impact of immunosuppression on coronary endothelial function after cardiac transplantation.

  1998cites this paper
• Islet transplantation: present and future perspectives.

  1998cites this paper
• A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group.

  1998cites this paper
• Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation

  1998cites this paper
• Atopic dermatitis: a question of balance.

  1998cites this paper
• The Influence of Some Immunosuppressive Drugs on the Metabolic Activity of Human Phagocytes and Lymphocytes in vitro

  1998cites this paper
• Thymus atrophy in the nonhuman primate by FK506: an immunohistochemical study.

  1997cites this paper
• FK506 potentiates steroid-induced T-cell apoptosis.

  1997cites this paper
• Inhibition by the immunosuppressive agent FK‐506 of antigen‐induced airways eosinophilia and bronchial hyperreactivity in mice

  1997cites this paper
• Serum interleukin-6 level after cardiac xenotransplantation in primates.

  1997cites this paper
• Maintenance Immunosuppressive Drug Therapy and Potential Major Complications

  1996cites this paper
• Induction of long-term graft tolerance and donor/recipient chimerism.

  1996cites this paper
• FK506 in liver transplantation for chronic hepatitis B: in vitro studies on lymphocyte activation and virus replication.

  1996cites this paper
• Effects of FK 506 on chimerism and the induction of donor-specific unresponsiveness following fully allogeneic bone marrow transplantation in mice.

  1995cites this paper
• INTERFERON-α-INDUCED ACUTE RENAL ALLOGRAFT REJECTION

  1995cites this paper
• FK506 in liver transplantation for chronic hepatitis B: In vitro studies on lymphocyte activation and virus replication

  1995cites this paper
• Interferon-alpha-induced acute renal allograft rejection.

  1995cites this paper
• Molecular identification of porcine interleukin 10: regulation of expression in a kidney allograft model.

  1995cites this paper
• FK506 augments activation-induced programmed cell death of T lymphocytes in vivo.

  1995cites this paper
• Differential effects of the immunosuppressants cyclosporin A, FK506 and KM2210 on cytokine gene expression.

  1995cites this paper
• Common and sequential overexpression patterns of T-helper cytokines during acute (cellular) rejection, and correlation of proinflammatory cytokine expression with chronic (ductopenic) rejection of human liver allografts: a study under cyclosporine, FK 506, and quadruple BT 563 immunosuppression.

  1995cites this paper
• The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival.

  1995cites this paper
• Comparative evaluation of tacrolimus (Fk506) and cyclosporin a as immunosuppressive agents

  1995cites this paper
• Distinct intragraft cytokine gene expression patterns during acute hepatic rejection under cyclosporine versus FK 506 primary immunosuppression.

  1994cites this paper
• FK506, an immunosuppressant, partially inhibits interleukin 6 production by adherent rheumatoid synovial cells.

  1994cites this paper
• Tacrolimus, a New Immunosuppressant—A Review of the Literature

  1994cites this paper
• Mechanism of FK506-induced glucose intolerance in rats.

  1994cites this paper
• Preventive effect of immunosuppressive agents against indomethacin-induced small intestinal ulcers in rats

  1994cites this paper
• FK506 and deoxyspergualin: experimental studies and clinical applications.

  1994cites this paper
• The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro.

  1994cites this paper
• Evidence that FK506 alleviates ischemia/reperfusion injury to the rat liver: in vivo demonstration for suppression of TNF-a production in response to endotoxemia.

  1994cites this paper
• Evaluation of sequential serum interleukin-6 levels in liver allograft recipients.

  1994cites this paper
• Serum cytokine levels after small bowel transplantation in pigs.

  1994cites this paper
• [New immunosuppressive therapies in kidney transplantation].

  1994cites this paper
• Short-term myeloid reconstitution following TBI is not adversely affected by doses of FK506 that abrogate lethal GVHD.

  1994cites this paper
• Inhibitory effect of FK506 on intercellular adhesion molecule-1 (ICAM-1) expression on cultured thyroid cells.

  1994cites this paper
• Inhibition by FK506 of formyl peptide-induced neutrophil activation and associated protein synthesis.

  1994cites this paper
• The effect of a short-course treatment with FK506 on the survivability of rat-to-mouse cross-species neural graft

  1993cites this paper
• FK506 inhibits phytohemagglutinin-, but not interferon-gamma-, induced HLA-DR antigen expression and accessory cell function on primary cultured human thyroid cells.

  1993cites this paper
• New immunosuppressive drugs: Mechanisms of action and early clinical experience

  1993cites this paper
• Prolonged survival of orthotopically transplanted heart xenograft in infant baboons.

  1993cites this paper
• Biological characteristics of a novel immunosuppressant, IR-1116, specific for B lymphocytes.

  1993cites this paper
• Graft Vessel Disease: The Impact of Immunosuppression and Possible Treatment Strategies

  1993cites this paper
• The immunobiology and clinical use of current immunosuppressive therapy for renal transplantation.

  1993cites this paper
• A modified method of mixed lymphocyte reaction: establishment of the assay system and its application to extracts of fungal cultures.

  1993cites this paper
• The changing face of liver transplantation.

  1993cites this paper
• Inhibition of human mononuclear cell proliferation, interleukin synthesis, mRNA for IL‐2, IL‐6, and leukotriene B4 synthesis by a lipoxygenase inhibitor

  1993cites this paper
• A DUAL MECHANISM OF IMMUNOSUPPRESSION BY FK‐506 DIFFERENTIAL SUPPRESSION OF IL‐4 AND IL‐10 LEVELS IN T HELPER 2 CELLS

  1993cites this paper
• Regulation of liver regeneration by interleukin-2 and its inhibitors: cyclosporine A and FK 506.

  1993cites this paper
• [FK506: an immunosuppressor for the '90's?].

  1993cites this paper
• Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

  1993cites this paper
• Novel derivatives at the C21 position of the FK-506 macrocycle

  1993cites this paper
• A novel immunosuppressant, IR‐1116, which has a different biological mechanism from that of cyclosporine A

  1993cites this paper
• Effects of immunosuppressants, FK506, deoxyspergualin, and cyclosporine A on immature human hematopoiesis.

  1993cites this paper
• Prevention of cyclophosphamide‐induced diabetes in the NOD/WEHI mouse with deoxyspergualin

  1993cites this paper
• New immunosuppressive agents.

  1993cites this paper
• Effects of Gamma‐Interferon and FK506 on Resting B Cell Proliferation of New Zealand Black/White F1 Mice

  1992cites this paper
• PPIase catalysis by human FK506-binding protein proceeds through a conformational twist mechanism.

  1992cites this paper
• FK 506 and cyclosporine inhibit antigen- or mitogen-induced monokine and lymphokine production in vitro.

  1992cites this paper
• THE DISTINCT EFFECTS OF FK506 ON THE ACTIVATION, PROLIFERATION, AND DIFFERENTIATION OF HUMAN B LYMPHOCYTES

  1992cites this paper
• THE EFFECTS OF FK506 AND CYCLOSPORINE ON THE EXOCRINE FUNCTION OF THE RAT PANCREAS

  1992cites this paper
• Molecular immunology and immunopharmacology of allograft rejection.

  1992cites this paper
• Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes.

  1992cites this paper
• Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases?

  1992cites this paper
• Molecular mode of action of cyclosporin and FK506 in human thymocytes.

  1992cites this paper
• Immunosuppressive mechanism of action of deoxymethylspergualin--a human in vitro assay.

  1992cites this paper
• A study on the timing of immunologic priming in autoimmune insulitis in NOD mice.

  1992cites this paper